MK-2060
Phase 1Completed 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
End-Stage Renal Disease
Conditions
End-Stage Renal Disease, Kidney Failure, Chronic
Trial Timeline
May 30, 2022 → Feb 14, 2023
NCT ID
NCT05335005About MK-2060
MK-2060 is a phase 1 stage product being developed by Merck for End-Stage Renal Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT05335005. Target conditions include End-Stage Renal Disease, Kidney Failure, Chronic.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05335005 | Phase 1 | Completed |
Competing Products
20 competing products in End-Stage Renal Disease